Antibiotic resistance inHaemophilus influenzae: mechanisms, clinical importance and consequences for therapy

Groot, Ronald de; Dzoljic-Danilovic, G.; Klingeren, B. Van; Goessens, W. H. F.; Neyens, H. J.

doi:10.1007/bf02072202

Cited by 21 publications

(9 citation statements)

References 157 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The MICs of TMP varied between 10 and 200 mg/liter for resistant isolates in comparison with MICs of Ͻ0.5 mg/liter for susceptible strains. In other species such intermediate levels of resistance usually reflect chromosomal mechanisms of resistance, and this was also shown to be the case with the Haemophilus isolates, which showed overproduction of altered chromosomal DHFR (32)(33)(34). Later cloning and sequencing work comparing susceptible and resistant Haemophilus strains showed changes in the Ϫ35 promoter sequence to make it homologous to that of E. coli mutants overproducing DHFR.…”

Section: Mechanisms Of Resistancementioning

confidence: 91%

See 1 more Smart Citation

Trimethoprim and sulfonamide resistance

Huovinen¹,

Sundström²,

Swedberg³

et al. 1995

Antimicrob Agents Chemother

445

314

View full text Add to dashboard Cite

Section: Mechanisms Of Resistancementioning

confidence: 91%

“…The most recent example of this third type of chromosomal resistance was found with clinical isolates of H. influenzae (32,34,126). The MICs of TMP varied between 10 and 200 mg/liter for resistant isolates in comparison with MICs of Ͻ0.5 mg/liter for susceptible strains.…”

Section: Mechanisms Of Resistancementioning

confidence: 99%

Trimethoprim and sulfonamide resistance

Huovinen¹,

Sundström²,

Swedberg³

et al. 1995

Antimicrob Agents Chemother

445

314

View full text Add to dashboard Cite

“…Treatment of such infections can be severely affected by antibiotic resistance. In H. influenzae resistance to antibiotics, especially to ␤-lactams, has, for a number of years, become a serious problem (6,15,30).Two main mechanisms are at the origin of resistance to aminopenicillins: enzymatic hydrolysis of the antibiotic and a change in penicillin-binding proteins (PBPs). By far the more frequent is the production of ␤-lactamase, usually of the TEM-1 type but sometimes of the ROB-1 type (15,32).…”

mentioning

confidence: 99%

mentioning

confidence: 99%

Diversity of β-Lactam Resistance-Conferring Amino Acid Substitutions in Penicillin-Binding Protein 3 of Haemophilus influenzae

Dabernat

Delmas

Seguy

et al. 2002

Antimicrob Agents Chemother

170

153

View full text Add to dashboard Cite

The sequences of the ftsI gene, encoding the transpeptidase domain of penicillin binding protein (PBP) 3A and/or PBP 3B, which are involved in septal peptidoglycan synthesis, were determined for 108 clinical strains of Haemophilus influenzae with reduced susceptibility to ␤-lactam antibiotics with or without ␤-lactamase production and were compared to those of the ampicillin-susceptible Rd strain and ampicillin-susceptible clinical isolates. The sequences have 18 different mutation patterns and were classified into two groups on the basis of amino acid substitutions deduced from the nucleotide sequences located between bp 960 and 1618 of the ftsI gene. In group I strains (n ‫؍‬ 7), His-517 was substituted for Arg-517. In group II strains (n ‫؍‬ 101), Lys-526 was substituted for Asn-526. In subgroup IIa (n ‫؍‬ 5; H. influenzae ATCC 49247), the only observed substitution was Lys-526 for Asn-526; in subgroup IIb (n ‫؍‬ 56), Val-502 was substituted for Ala-502 (n ‫؍‬ In spite of the widespread use of the anti-Haemophilus b vaccine in the industrialized countries and the decreased incidence of invasive diseases (18), Haemophilus influenzae remains a key species in bronchopulmonary and ear, nose, and throat (ENT) infections in both adults and children. These diseases are most often caused by noncapsulated strains (10,14). Treatment of such infections can be severely affected by antibiotic resistance. In H. influenzae resistance to antibiotics, especially to ␤-lactams, has, for a number of years, become a serious problem (6,15,30).Two main mechanisms are at the origin of resistance to aminopenicillins: enzymatic hydrolysis of the antibiotic and a change in penicillin-binding proteins (PBPs). By far the more frequent is the production of ␤-lactamase, usually of the TEM-1 type but sometimes of the ROB-1 type (15,32). In certain countries, the incidence of strains producing ␤-lactamase is particularly high, reaching 50% in type b strains, which are responsible for invasive manifestations (before anti-Haemophilus b vaccination), and 20 to 30% in noncapsulated strains that lead to bronchopulmonary and ENT infections (5, 12, 32).Resistance by mechanisms other than ␤-lactamase production is based on decreased affinity of the PBPs involved in septal peptidoglycan synthesis (4). The first observations of ampicillin-resistant non-␤-lactamase producing (BLNAR) strains were reported in the early 1980s and concerned type b capsulated (20, 27) and noncapsulated strains (2, 25). In contrast to the incidence of ␤-lactamase-producing strains, the incidence of BLNAR strains remains low in various countries (4,5,8,32), but in Japan the proportion of BLNAR clinical isolates is more than 25% and seems to be increasing (33,36).In H. influenzae, ampicillin resistance unrelated to ␤-lactamase production was shown to be chromosomally mediated and was correlated with alterations in PBPs 3A and 3B (4,22,29,34). Recently, Ubukata et al. (36) demonstrated that mutations in the ftsI gene, which is involved in septal peptidoglycan synthesis, are th...

show abstract

“…Резистентність Haemophilus influenzae до ампіциліну й амоксициліну, а також до цефалоспоринів пов'язана з продукцією плазмідних ферментів ТЕМ-1 (пеніцилінази) β-лактамаз, що становлять понад 90 % від числа всіх β-лактамазопродукуючих штамів [19]. Крім плазмідної резистентності, у близько 8 % штамів резистентність до β-лактамів обумовлена синтезом хромосомної β-лактамази ROB-1 [20]. Було встановлено, що резистентність грамнегативних бактерій, у тому числі Haemophilus influenzae, пов'язана з біосинтезом мікроорганізмами ензимів, генетично пов'язаних з β-лактамазами широкого спектра.…”

Section: таблиця 1 частота виділення бактеріальних збудників респіраunclassified

Результаты Микробиологического Мониторинга Бактериальных Возбудителей Респираторного Тракта У Детей За 2017 Год

Lezhenko¹,

Pashkovа²

2021

View full text Add to dashboard Cite

В работе приведены результаты бактериологического мониторинга в течение 2017 года 483 детей из г. Запорожья и Запорожской области в возрасте от 3 до 14 лет, больных острыми респираторными заболеваниями. Установлено, что при наличии бактериальной этиологии респираторной инфекции ведущими возбудителями были Streptococcus pneumoniae (49,4 %) и бактерии рода Haemophilus (36,2 %). Проведенный анализ антибиотикограммы показал, что наибольшую чувствительность указанные микроорганизмы проявляли к цефалоспоринам III–IV поколения, ванкомицину, линезолиду и левофлоксацину. Отмечалась высокая антибиотикорезистентность Streptococcus pneumoniaе к пенициллину (56,0 % штаммов), клиндамицину (43,0 % штаммов) и эритромицину (45,0 % штаммов). Изоляты бактерий рода Haemophilus наиболее часто проявляли резистентность к ампициллину (58,1 % штаммов) и защищенным пенициллинам (52 % штаммов). На основе полученных данных обоснована целесообразность применения антибиотика из группы цефалоспоринов III поколения цефподоксима проксетила в качестве стартового антибактериального препарата в терапии острой бактериальной респираторной инфекции у детей.

show abstract

Antibiotic resistance inHaemophilus influenzae: mechanisms, clinical importance and consequences for therapy

Cited by 21 publications

References 157 publications

Trimethoprim and sulfonamide resistance

Trimethoprim and sulfonamide resistance

Diversity of β-Lactam Resistance-Conferring Amino Acid Substitutions in Penicillin-Binding Protein 3 of Haemophilus influenzae

Результаты Микробиологического Мониторинга Бактериальных Возбудителей Респираторного Тракта У Детей За 2017 Год

Contact Info

Product

Resources

About